Connecticut Settled $96M Generic Drug Price-Fixing Case
Consumers who purchased certain generic medications between 2009 and 2019 may now file for settlement compensation.
Updated on Sept. 22, 2026 in Healthcare
Live Poll
Do you trust that consumer price-fixing settlements provide fair compensation to affected individuals?
Connecticut reached a $96 million settlement with six generic drug manufacturers following allegations of a conspiracy to artificially inflate medication prices. Eligible residents who purchased specific prescriptions between 2009 and 2019 can now begin submitting claims for restitution.
Why it matters
The settlement addresses long-standing accusations that manufacturers rigged the generic drug market to drive up consumer costs. This legal resolution provides a pathway for impacted patients to recover funds lost during a decade of alleged price manipulation.
The state secured a $96 million settlement fund from six manufacturers to address price-fixing allegations. This covers qualifying drug purchases made throughout a ten-year window ending in 2019.
The players
Glenmark
A pharmaceutical company that develops and manufactures generic drugs for global markets.
Lannett
A manufacturer and distributor of generic pharmaceutical products.
Bausch
A multinational pharmaceutical firm focused on eye health and generic medications.
Apotex
A global producer of generic medications and biosimilars.
Heritage
A pharmaceutical manufacturer specializing in the development of generic medicines.
The details
The settlement follows allegations that companies coordinated to restrict competition and inflate prices for drugs including albuterol, prednisone, and warfarin sodium. Glenmark, Lannett, Bausch, Apotex, Heritage, and Emcure are among the manufacturers involved in the agreement. Residents can process claims through the portal facilitated by the Attorney General's office.
Timeline
Eligible generic medication purchases were made between 2009 and 2019.
Market Landscape
This settlement follows the established pattern of multi-state generic drug price-fixing litigation. It marks a significant effort to address anti-competitive behavior that has impacted pharmaceutical pricing trends over the last decade.
Businesses and individuals who purchased specific generics like albuterol or prednisone between 2009 and 2019 should review their records for eligibility. Consult with your accountant or legal counsel to determine if your previous procurement qualifies for inclusion in the settlement process.
The takeaway
This settlement concludes a major chapter in market-wide litigation concerning anti-competitive pharmaceutical pricing. Operators should monitor their records for legacy procurement of the specified drugs to determine if they meet the criteria for restitution.
Further reading
For broader trends in the industry, see the latest updates on Healthcare.
More information
To file a claim or verify eligibility, visit the generic drug settlement claim portal.
Live Poll
Do you trust that consumer price-fixing settlements provide fair compensation to affected individuals?
